Document Reference: PH-STA-166

Document Issue Number:

Document Issue Date:

Page 1 of 1

01 08/10/2024 Polyco Healthline

Tel: +44 (0)33 3320 8550

## **Chemotherapy Permeation Statement**

| Product Brand:              | PH Handsafe                                  |  |
|-----------------------------|--|--|
| <b>Product Description:</b> | Powder Free White Nitrile Examination Gloves |  |
| Product Code:               | GN92   |  |

The Polyco Healthline GN92 white HandSafe nitrile examination grade gloves were submitted by the OEM factory to Akron Rubber Development Laboratory Inc. for testing in accordance with ASTM D6978-05: Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs (test report references: PN122551).

## Minimum Break Through Time – GN92 White Nitrile Gloves

| Test Chemical              | Concentration        | Minimum<br>Breakthrough<br>Time - minutes | Suitability |
|----------------------------|----------------------|---|-------------|
| Carmustine (BCNU)          | 3.3 mg/ml 3,300ppm   | 10.1                                      | No          |
| Cisplatin                  | 1.0 mg/ml 1,000ppm   | No Breakthrough up to 240 Mins.           | Yes         |
| Cyclophosphamide (Cytoxan) | 20.0 mg/ml 20,000ppm | No Breakthrough up to 240 Mins.           | Yes         |
| Dacarbazine                | 10.0 mg/ml 10,000ppm | No Breakthrough up to 240 Mins.           | Yes         |
| Doxorubicin Hydrochloride  | 2.0 mg/ml 2,000ppm   | No Breakthrough up to 240 Mins.           | Yes         |
| Etoposide (Toposar)        | 20.0 mg/ml 20,000ppm | No Breakthrough up to 240 Mins.           | Yes         |
| Fluorouracil               | 50.0 mg/ml 50,000ppm | No Breakthrough up to 240 Mins.           | Yes         |
| Paclitaxel (Taxol)         | 6.0 mg/ml 6,000ppm   | No Breakthrough up to 240 Mins.           | Yes         |
| Thiotepa                   | 10.0 mg/ml 10,000ppm | 20.2                                      | No          |

Karen Gunning QA and Regulatory Affairs Department

08th October 2024